Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Citius Pharmaceuticals ( (CTXR) ) just unveiled an update.
On October 20, 2025, Citius Pharmaceuticals entered into a securities purchase agreement with an institutional investor for a registered direct offering of common stock and pre-funded warrants, closing on October 21, 2025. The offering raised approximately $6 million in gross proceeds, with net proceeds intended to support the commercial launch of LYMPHIR, development initiatives, and general corporate purposes. H.C. Wainwright & Co. acted as the exclusive placement agent, receiving a cash fee and warrants as compensation. The offering aligns with Citius’s strategy to enhance its market position and fund its pipeline advancements.
The most recent analyst rating on (CTXR) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Citius Pharmaceuticals stock, see the CTXR Stock Forecast page.
Spark’s Take on CTXR Stock
According to Spark, TipRanks’ AI Analyst, CTXR is a Underperform.
Citius Pharmaceuticals’ overall stock score reflects the challenging financial performance and bearish technical indicators. The company’s ongoing losses, reliance on external financing, and negative cash flows are significant concerns. The stock’s downward momentum and negative valuation metrics further contribute to the low score. The biotech firm remains speculative, hinging on future revenue generation and operational improvements.
To see Spark’s full report on CTXR stock, click here.
More about Citius Pharmaceuticals
Citius Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing first-in-class critical care products. The company’s portfolio includes LYMPHIR, an FDA-approved targeted immunotherapy for cutaneous T-cell lymphoma, Mino-Lok, an antibiotic lock solution for catheter-related bloodstream infections, and CITI-002 (Halo-Lido), a topical formulation for hemorrhoids. Citius is actively engaging with the FDA to advance its late-stage pipeline.
Average Trading Volume: 699,214
Technical Sentiment Signal: Sell
Current Market Cap: $30.79M
Find detailed analytics on CTXR stock on TipRanks’ Stock Analysis page.